胰臟癌診斷市場－全球產業規模、佔有率、趨勢、機會、預測：按檢測類型、癌症類型、最終用戶、地區和競爭格局分類，2021-2031年

全球胰臟癌診斷市場預計將從 2025 年的 30.1 億美元成長到 2031 年的 45.9 億美元，複合年成長率為 7.29%。

該市場涵蓋多種醫療檢測，包括生物標記檢測、分子診斷、切片檢查技術和先進影像技術。推動市場成長的主要因素包括全球發病率上升、死亡率高、早期檢測面臨挑戰，以及對人工智慧影像和非侵入性液態生物檢體等先進工具日益成長的需求。美國癌症協會預測，到2025年，美國將有67,440人被診斷出罹患胰臟癌，這進一步凸顯了對更佳診斷方案的迫切需求。然而，高昂的成本以及某些地區最尖端科技的普及程度有限，仍然限制市場成長，並常常導致關鍵患者治療的延誤。

市場促進因素

推動診斷市場擴張的主要因素之一是全球胰臟癌發生率的上升。這促使人們對更便利、更有效率的診斷設備的需求日益成長，以便早期發現疾病並改善患者預後。病例的持續增加凸顯了在更易治療的階段識別這種高致死率癌症的重要性。 2026年1月，盧斯特加滕基金會的一份報告也指出了這一點，該報告引述美國癌症協會的數據，強調自1990年代以來，胰臟癌的發生率每年成長約1%。同時，人工智慧、先進影像和液態生物檢體等診斷技術的突破性進展，透過提供更準確、創傷更小的分期和檢測方案，正在顯著影響市場。合作研究和資金投入正在進一步加速這一進程。例如，NVIDIA 於 2025 年 8 月與 12 家全球機構合作，建立了一個全面的胰臟 CT 資料集；AIM ImmunoTech 於 2026 年 4 月發行了新的股份認購權，為轉移性胰臟癌的研究籌集了約 180 萬美元。

市場挑戰

全球胰臟癌診斷市場受到高成本和先進診斷工具普及率低的嚴重限制。購買和維護先進的影像系統、分子診斷平台和複雜的生物標記檢測需要大量資金，這限制了這些技術的應用，尤其是在預算有限的醫療機構和發展中地區。因此，檢測數量正在減少，減緩了整體市場的發展。此外，這些專業技術的普及不足導致診斷嚴重延誤，直接影響患者的預後。魯斯特加滕基金會引述美國癌症協會2026年的報告指出，只有17%的患者在局部（即治療效果最佳的階段）得到診斷。這凸顯了先進診斷資源的嚴重匱乏，而經濟障礙和資源取得方面的不平等也持續限制著市場覆蓋範圍和成長潛力。

市場趨勢

全球胰臟癌診斷市場正受到次世代定序(NGS) 和先進分子譜分析技術的顯著影響。這些技術能夠更深入地了解腫瘤的生物學特徵，並支持制定個人化治療方案。這些先進檢測技術的普及和醫保報銷範圍的擴大正在推動其在臨床上的廣泛應用。 2026 年 1 月，Illumina 公司獲得 FDA已通過核准的TruSight 檢測獲得了美國醫療保險和醫療補助服務中心 (CMS) 2,989.55 美元的報銷，這為聯邦醫療保險 (Medicare) 受益人鋪平了道路，並促進了市場整合。同時，多癌種早期檢測系統的興起標誌著預防性篩檢的重大轉變，使得即使在無症狀個體中也能識別出胰臟癌和其他癌症。像 Guardant Health 的 Shield 血液檢測這樣的創新技術，在 2025 年 6 月的一項研究中，對胰腺癌的敏感性達到了 68%，並獲得了 FDA 突破性醫療器械的認定，對於不斷擴大的診斷市場和提高這種疾病的早期檢測率至關重要，而胰腺癌的診斷往往被延誤。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球胰臟癌診斷市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 檢查類型{影像診斷測試（電腦斷層掃描、MRI、超音波等）}
  • 癌症類型（外分泌癌症、腺癌、鱗狀細胞癌、膠狀癌、其他）
  • 依最終使用者（醫院/診所、診斷中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美胰臟癌診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲胰臟癌診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區胰臟癌診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲胰臟癌診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲胰臟癌診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球胰臟癌診斷市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Siemens Healthineers AG
• Myriad Genetics, Inc.
• Pfizer, Inc
• Novartis AG
• AstraZeneca plc
• Immunovia AB
• Laboratory Corporation of America Holdings
• Abbott Laboratories
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Pancreatic Cancer Diagnostics Market is anticipated to expand from USD 3.01 Billion in 2025 to USD 4.59 Billion by 2031, reflecting a 7.29% CAGR, and encompasses a variety of medical tests such as biomarker assays, molecular diagnostics, biopsy techniques, and advanced imaging. Growth is primarily stimulated by the increasing worldwide prevalence of the disease, its severe mortality rates, the challenges associated with early detection, and a rising need for sophisticated tools like AI-enhanced imaging and non-invasive liquid biopsies. Highlighting the critical demand for better diagnostic solutions, the American Cancer Society projects that 67,440 people in the U.S. will be diagnosed with pancreatic cancer in 2025. However, market growth continues to be hindered by the steep costs and restricted availability of these cutting-edge technologies in certain areas, which often postpones essential patient treatment.

Market Driver

A major catalyst for the expansion of the diagnostics market is the increasing global rate of pancreatic cancer, which drives the need for more accessible and efficient diagnostic instruments to catch the disease early and enhance patient prognosis. The continuous rise in cases emphasizes the critical need to identify this highly fatal cancer at more manageable stages, as noted in a January 2026 report by the Lustgarten Foundation citing the American Cancer Society, which highlighted a roughly 1% annual incidence increase since the 1990s. Simultaneously, breakthroughs in diagnostic methods, including artificial intelligence, advanced imaging, and liquid biopsies, are profoundly shaping the market by providing more accurate and less invasive staging and detection options. Collaborative efforts and funding are further accelerating this progress, exemplified by NVIDIA's August 2025 partnership with 12 global institutions to build a comprehensive pancreatic CT dataset, and AIM ImmunoTech's April 2026 rights offering that secured around $1.8 million for metastatic pancreatic cancer research.

Market Challenge

The expansion of the Global Pancreatic Cancer Diagnostics Market is significantly hindered by the high costs and limited availability of cutting-edge diagnostic tools. The substantial financial investment needed to purchase and upkeep sophisticated imaging systems, molecular platforms, and complex biomarker assays limits their integration, especially within budget-restricted healthcare networks and developing regions, thereby reducing testing volumes and slowing overall market progress. Additionally, this lack of widespread access to specialized technologies directly compromises patient outcomes by delaying crucial diagnoses. The Lustgarten Foundation, referencing the American Cancer Society's 2026 report, noted that a mere 17% of patients receive a diagnosis at a localized, highly treatable stage, underscoring a major shortfall in the application of advanced diagnostic resources as financial barriers and unequal access continue to restrict the market's reach and growth potential.

Market Trends

The Global pancreatic cancer diagnostics market is being heavily shaped by next-generation sequencing and advanced molecular profiling, which provide a profound understanding of tumor biology to help tailor personalized treatment plans. The growing accessibility and expanding reimbursement options for these sophisticated tests are encouraging broader clinical use, as seen in January 2026 when Illumina's FDA-approved TruSight test secured CMS reimbursement at $2,989.55, smoothing the path for Medicare patients and boosting market integration. Concurrently, the rise of multi-cancer early detection systems represents a crucial shift toward proactive screening, allowing for the identification of pancreatic and other cancers in individuals without symptoms. Innovations like Guardant Health's Shield blood test, which achieved a 68% sensitivity rate for pancreatic cancer in a June 2025 study and earned FDA Breakthrough Device status, are vital for expanding the diagnostic market and improving early detection for this notoriously late-diagnosed disease.

Key Market Players

• Siemens Healthineers AG
• Myriad Genetics, Inc.
• Pfizer, Inc
• Novartis AG
• AstraZeneca plc
• Immunovia AB
• Laboratory Corporation of America Holdings
• Abbott Laboratories
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global Pancreatic Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pancreatic Cancer Diagnostics Market, By Test Type {Diagnostic Imaging Tests

• CT scan
• MRI
• Ultrasound
• Others

Pancreatic Cancer Diagnostics Market, By Cancer Type

• Exocrine
• Adenocarcinoma
• Squamous Cell Carcinoma
• Colloid Carcinoma
• Others

Pancreatic Cancer Diagnostics Market, By End User

• Hospitals & Clinics
• Diagnostic Centers
• Others

Pancreatic Cancer Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pancreatic Cancer Diagnostics Market.

Available Customizations:

Global Pancreatic Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pancreatic Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type {Diagnostic Imaging Tests (CT scan, MRI, Ultrasound, Others)
  • 5.2.2. By Cancer Type (Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Colloid Carcinoma, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Pancreatic Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type {Diagnostic Imaging Tests
  • 6.2.2. By Cancer Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pancreatic Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type {Diagnostic Imaging Tests
      • 6.3.1.2.2. By Cancer Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Pancreatic Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type {Diagnostic Imaging Tests
      • 6.3.2.2.2. By Cancer Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Pancreatic Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type {Diagnostic Imaging Tests
      • 6.3.3.2.2. By Cancer Type
      • 6.3.3.2.3. By End User

7. Europe Pancreatic Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type {Diagnostic Imaging Tests
  • 7.2.2. By Cancer Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type {Diagnostic Imaging Tests
      • 7.3.1.2.2. By Cancer Type
      • 7.3.1.2.3. By End User
  • 7.3.2. France Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type {Diagnostic Imaging Tests
      • 7.3.2.2.2. By Cancer Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type {Diagnostic Imaging Tests
      • 7.3.3.2.2. By Cancer Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type {Diagnostic Imaging Tests
      • 7.3.4.2.2. By Cancer Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Pancreatic Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type {Diagnostic Imaging Tests
      • 7.3.5.2.2. By Cancer Type
      • 7.3.5.2.3. By End User

8. Asia Pacific Pancreatic Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type {Diagnostic Imaging Tests
  • 8.2.2. By Cancer Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type {Diagnostic Imaging Tests
      • 8.3.1.2.2. By Cancer Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type {Diagnostic Imaging Tests
      • 8.3.2.2.2. By Cancer Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type {Diagnostic Imaging Tests
      • 8.3.3.2.2. By Cancer Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type {Diagnostic Imaging Tests
      • 8.3.4.2.2. By Cancer Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Pancreatic Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type {Diagnostic Imaging Tests
      • 8.3.5.2.2. By Cancer Type
      • 8.3.5.2.3. By End User

9. Middle East & Africa Pancreatic Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type {Diagnostic Imaging Tests
  • 9.2.2. By Cancer Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pancreatic Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type {Diagnostic Imaging Tests
      • 9.3.1.2.2. By Cancer Type
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Pancreatic Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type {Diagnostic Imaging Tests
      • 9.3.2.2.2. By Cancer Type
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Pancreatic Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type {Diagnostic Imaging Tests
      • 9.3.3.2.2. By Cancer Type
      • 9.3.3.2.3. By End User

10. South America Pancreatic Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type {Diagnostic Imaging Tests
  • 10.2.2. By Cancer Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pancreatic Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type {Diagnostic Imaging Tests
      • 10.3.1.2.2. By Cancer Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Pancreatic Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type {Diagnostic Imaging Tests
      • 10.3.2.2.2. By Cancer Type
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Pancreatic Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type {Diagnostic Imaging Tests
      • 10.3.3.2.2. By Cancer Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pancreatic Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Siemens Healthineers AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Myriad Genetics, Inc.
• 15.3. Pfizer, Inc
• 15.4. Novartis AG
• 15.5. AstraZeneca plc
• 15.6. Immunovia AB
• 15.7. Laboratory Corporation of America Holdings
• 15.8. Abbott Laboratories
• 15.9. Agilent Technologies, Inc.
• 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer